Anti-CD19 CAR T-cell therapy in relapsed/refractory T-cell/histiocyte-rich large B-cell lymphoma: insights from the French DESCAR-T registry, a LYSA study

Authors

Axel André,[1] Estelle Bourbon,[2] Guillaume Cartron,[3] Franck Morschhauser,[4] Amandine Fayard,[5] Laure Ricard,[6] Roberta Di Blasi,[7] Adrien Chauchet,[8] Stéphanie Guidez,[9] Cristina Castilla-Llorente,[10] Gabriel Brisou,[11] Pierre Bories,[12] Roch Houot,[13] Anne Cuozzo-Minaï,[14] Elodie Gat,[14] François Lemonnier[1] and Camille Laurent[15]

[1]AP-HP, Hôpital Henri Mondor, Université Paris Est Créteil, Paris; [2]CHU Lyon-Sud, Lyon; [3]CHU de Montpellier, Montpellier; [4]CHU de Lille, Hôpital Claude Huriez, Lille; [5]CHU Estaing, Clermont-Ferrand; [6]AP-HP, Hôpital Saint-Antoine, Paris; [7]AP-HP, Hôpital Saint-Louis, Paris; [8]CHU Jean Minjoz, Besançon; [9]CHU de Poitiers, Hôpital de la Milétrie, Poitiers; [10]Gustave Roussy Cancer Campus Grand Paris, Villejuif; [11]Institut Paoli-Calmettes, Marseille; [12]Institut Universitaire du Cancer Toulouse – Oncopole, Toulouse; [13]CHU Pontchaillou, Rennes; [14]LYSARC, Lyon and [15]Department of Bio-Pathology, Institut Universitaire du Cancer-Oncopole, Université Toulouse, Centre de Recherches en Cancérologie de Toulouse INSERM U1037, Toulouse, France


Correspondence:
A. ANDRÉ - axelandre@msn.com

https://doi.org/10.3324/haematol.2025.289196

Received: September 25, 2025.
Accepted: March 30, 2026.
Early view: April 9, 2026.

©2026 Ferrata Storti Foundation
Published under a CC BY-NC license

Supplementary Figure 1. Impact of an associated low-grade lymphoma on survival after CAR T-cell therapy in THRLBCL.



	No. of subjects	Event	Censored	Median survival (95% CI)
No	16	68.8 % (11)	31.3 % (5)	3.5 (1.0 ; NA)
Yes	7	85.7 % (6)	14.3 % (1)	2.2 (1.1 ; NA)

Supplementary Figure 1. Kaplan–Meier estimates of progression-free survival (PFS) after CAR T-cell therapy according to the presence ("Yes" blue curve, n=7) or absence ("No" red curve, n=16) of an associated low-grade lymphoma (log-rank p=0.11).